CN101677942B - 阿帕兹醌在制造切除膀胱肿瘤后治疗膀胱癌的药物的用途 - Google Patents

阿帕兹醌在制造切除膀胱肿瘤后治疗膀胱癌的药物的用途 Download PDF

Info

Publication number
CN101677942B
CN101677942B CN2008800159754A CN200880015975A CN101677942B CN 101677942 B CN101677942 B CN 101677942B CN 2008800159754 A CN2008800159754 A CN 2008800159754A CN 200880015975 A CN200880015975 A CN 200880015975A CN 101677942 B CN101677942 B CN 101677942B
Authority
CN
China
Prior art keywords
bladder
tur
patients
use according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800159754A
Other languages
English (en)
Chinese (zh)
Other versions
CN101677942A (zh
Inventor
路吉·莱纳兹
尚塔·乔拉
马里奥·比尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of CN101677942A publication Critical patent/CN101677942A/zh
Application granted granted Critical
Publication of CN101677942B publication Critical patent/CN101677942B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008800159754A 2007-03-13 2008-03-13 阿帕兹醌在制造切除膀胱肿瘤后治疗膀胱癌的药物的用途 Expired - Fee Related CN101677942B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89461007P 2007-03-13 2007-03-13
US60/894,610 2007-03-13
PCT/US2008/056912 WO2008112934A1 (en) 2007-03-13 2008-03-13 Intravesical apaziquone administration following transurethral resection for treating cancer

Publications (2)

Publication Number Publication Date
CN101677942A CN101677942A (zh) 2010-03-24
CN101677942B true CN101677942B (zh) 2013-10-30

Family

ID=39494173

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800159754A Expired - Fee Related CN101677942B (zh) 2007-03-13 2008-03-13 阿帕兹醌在制造切除膀胱肿瘤后治疗膀胱癌的药物的用途

Country Status (17)

Country Link
US (1) US20080227841A1 (cg-RX-API-DMAC10.html)
EP (1) EP2134322B1 (cg-RX-API-DMAC10.html)
JP (2) JP5788143B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090128479A (cg-RX-API-DMAC10.html)
CN (1) CN101677942B (cg-RX-API-DMAC10.html)
AR (1) AR065732A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008224962B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0808804A2 (cg-RX-API-DMAC10.html)
CA (1) CA2680481C (cg-RX-API-DMAC10.html)
ES (1) ES2727257T3 (cg-RX-API-DMAC10.html)
IL (1) IL200899A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009009777A (cg-RX-API-DMAC10.html)
NZ (1) NZ579609A (cg-RX-API-DMAC10.html)
RU (2) RU2480200C2 (cg-RX-API-DMAC10.html)
TW (1) TWI434684B (cg-RX-API-DMAC10.html)
WO (1) WO2008112934A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200906328B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201213486D0 (en) * 2012-07-30 2012-09-12 Univ Salford The Quinone compounds and their uses for the treatment of cancer
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178305C1 (ru) * 2000-11-02 2002-01-20 Гарбер Александр Григорьевич Ирригационный раствор
EP2060259B1 (en) * 2001-11-01 2010-01-20 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
RU2002121829A (ru) * 2002-08-07 2004-02-27 Сгму Способ лечения местнораспространенных форм рака мочевого пузыря

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Phase Ⅰ/Ⅱ pilot study of intravesical apaziquone (E09) for superficial bladder cancer;PURI ET AL;《JOURNAL OF UROLOGY》;20061001;第176卷(第4期);文章摘要，第1347页 *

Also Published As

Publication number Publication date
MX2009009777A (es) 2009-11-26
RU2012157329A (ru) 2014-07-10
AR065732A1 (es) 2009-06-24
RU2009137770A (ru) 2011-04-20
AU2008224962A1 (en) 2008-09-18
ES2727257T3 (es) 2019-10-15
CA2680481C (en) 2016-06-21
AU2008224962B2 (en) 2013-07-25
RU2480200C2 (ru) 2013-04-27
TW200904410A (en) 2009-02-01
CA2680481A1 (en) 2008-09-18
ZA200906328B (en) 2010-05-26
RU2623142C2 (ru) 2017-06-22
NZ579609A (en) 2012-01-12
EP2134322A1 (en) 2009-12-23
CN101677942A (zh) 2010-03-24
US20080227841A1 (en) 2008-09-18
KR20090128479A (ko) 2009-12-15
WO2008112934A1 (en) 2008-09-18
BRPI0808804A2 (pt) 2014-08-19
JP2014028841A (ja) 2014-02-13
TWI434684B (zh) 2014-04-21
EP2134322B1 (en) 2019-02-20
IL200899A0 (en) 2010-05-17
JP2010521488A (ja) 2010-06-24
JP5788143B2 (ja) 2015-09-30

Similar Documents

Publication Publication Date Title
US20100216755A1 (en) Anti-tumor agent
CN101389343B (zh) 抗癌用阿霉素制剂
JP2002544229A (ja) 癌の化学的予防および治療のために組み合わせたｄｆｍｏおよびセレコキシブ
KR20210053948A (ko) 겸상 세포 질환의 치료를 위한 pde9 억제제
US20150190413A1 (en) Compositions and methods for the treatment of bladder cancer
Warshawsky et al. Bilateral renal aspergillosis
EP3407887B1 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
CA2680481C (en) Intravesical apaziquone administration following transurethral resection for treating cancer
JP7237362B2 (ja) 急性腎不全の治療における使用のためのアンブリセンタン
KR20200051690A (ko) 국소 조성물
KR101544222B1 (ko) 유두상 신세포암에서의 템시로리무스의 항종양 활성
CN118634316A (zh) 一种预防和治疗胆汁淤积症的司美格鲁肽联合用药组合物
IL322689A (en) Compositions and methods of using eflornithine
Sweatman et al. Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study
CN1901906B (zh) 治疗套细胞淋巴瘤的cci-779
US12226433B2 (en) Treatment of irritable bowel syndrome with molybdenum
US8273721B2 (en) Combination treatment for bladder cancer
HK40000014B (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131030

Termination date: 20200313

CF01 Termination of patent right due to non-payment of annual fee